Clinical trial
Efficacy and Safety of Co-administration of Omacor Plus Atorvastatin Compared With Atorvastatin Monotherapy in Patients With Type Ⅱb Dyslipidemia: a Multicenter, Double-blind, Randomized, Active-controlled, Parallel, Phase Ⅲ Study
NCT02035215 is registered in ClinicalTrials.gov with Kuhnil Pharmaceutical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy and Safety of Co-administration of Omacor Plus Atorvastatin Compared With Atorvastatin Monotherapy in Patients With Type Ⅱb Dyslipidemia: a Multicenter, Double-blind, Randomized, Active-controlled, Parallel, Phase Ⅲ Study
- Lead sponsor
- Kuhnil Pharmaceutical Co., Ltd.
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- January 31, 2014
- Completion date
- December 31, 2014
- Enrollment
- 80 (estimated)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.